Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside

Full Text

Immunotherapy

Posted online on May 10, 2016.

(doi:10.2217/imt-2016-0049)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License

Chantal Kuhn¹ & Howard L Weiner*^,1

*Author for correspondence: hweiner@rics.bwh.harvard.edu

Sections: 

ChooseABSTRACTBackgroundTregs in autoimmune disea...Anti-CD3 mAb in animal mo...New mouse models for test...Oral administration of an...How does oral anti-CD3 mA...Nasal administration of a...Clinical development of a...Clinical trials with intr...Clinical trials with oral...Combination therapies wit...Combination therapies wit...Conclusion & future persp...References

ABSTRACT	ChooseTop of pageABSTRACT <<BackgroundTregs in autoimmune disea...Anti-CD3 mAb in animal mo...New mouse models for test...Oral administration of an...How does oral anti-CD3 mA...Nasal administration of a...Clinical development of a...Clinical trials with intr...Clinical trials with oral...Combination therapies wit...Combination therapies wit...Conclusion & future persp...References

The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20 years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune disease in animal models and have also shown promise in clinical trials. Tolerance induction by anti-CD3 mAbs is related to the induction of Tregs that control pathogenic autoimmune responses. Here, we review preclinical and clinical studies in which intravenous or mucosal administration of anti-CD3 mAbs has been employed and provide an outlook on future developments to enhance the efficacy of this promising therapeutic approach.

View/Print PDF (8572 KB)

View PDF Plus (8719 KB)